Johnson & Johnson Gross Margin 2010-2024 | JNJ

Current and historical gross margin for Johnson & Johnson (JNJ) over the last 10 years. The current gross profit margin for Johnson & Johnson as of March 31, 2024 is %.
Johnson & Johnson Gross Margin Historical Data
Date TTM Revenue TTM Gross Profit Gross Margin
2024-03-31 $85.65B $59.27B 69.20%
2023-12-31 $85.16B $58.61B 68.82%
2023-09-30 $80.32B $55.91B 69.61%
2023-06-30 $78.97B $54.99B 69.64%
2023-03-31 $77.46B $53.77B 69.42%
2022-12-31 $79.99B $55.39B 69.25%
2022-09-30 $77.21B $54.02B 69.96%
2022-06-30 $80.55B $56.28B 69.87%
2022-03-31 $79.85B $55.91B 70.02%
2021-12-31 $78.74B $55.34B 70.28%
2021-09-30 $91.45B $61.73B 67.51%
2021-06-30 $89.19B $59.75B 67.00%
2021-03-31 $84.21B $55.79B 66.24%
2020-12-31 $82.58B $54.16B 65.58%
2020-09-30 $80.86B $53.11B 65.68%
2020-06-30 $80.50B $52.86B 65.66%
2020-03-31 $82.73B $54.73B 66.15%
2019-12-31 $82.06B $54.50B 66.42%
2019-09-30 $81.71B $54.32B 66.49%
2019-06-30 $81.33B $54.22B 66.67%
2019-03-31 $81.59B $54.50B 66.80%
2018-12-31 $81.58B $54.49B 66.79%
2018-09-30 $81.38B $53.99B 66.35%
2018-06-30 $80.68B $52.96B 65.64%
2018-03-31 $78.69B $52.05B 66.14%
2017-12-31 $76.45B $51.01B 66.72%
2017-09-30 $74.36B $50.54B 67.97%
2017-06-30 $72.53B $50.15B 69.15%
2017-03-31 $72.17B $50.31B 69.70%
2016-12-31 $71.89B $50.10B 69.69%
2016-09-30 $71.60B $49.77B 69.52%
2016-06-30 $70.88B $49.32B 69.58%
2016-03-31 $70.18B $48.60B 69.25%
2015-12-31 $70.07B $48.54B 69.27%
2015-09-30 $70.52B $48.80B 69.20%
2015-06-30 $71.88B $49.99B 69.55%
2015-03-31 $73.59B $51.02B 69.33%
2014-12-31 $74.33B $51.59B 69.40%
2014-09-30 $74.43B $51.58B 69.30%
2014-06-30 $73.54B $50.75B 69.01%
2014-03-31 $71.92B $49.68B 69.07%
2013-12-31 $71.31B $48.97B 68.67%
2013-09-30 $70.52B $48.13B 68.25%
2013-06-30 $69.99B $47.35B 67.65%
2013-03-31 $68.59B $46.29B 67.49%
2012-12-31 $67.22B $45.57B 67.78%
2012-09-30 $65.92B $44.93B 68.15%
2012-06-30 $64.87B $44.41B 68.45%
2012-03-31 $65.00B $44.50B 68.46%
2011-12-31 $65.03B $44.67B 68.69%
2011-09-30 $64.42B $44.36B 68.86%
2011-06-30 $63.40B $43.81B 69.11%
2011-03-31 $62.13B $43.09B 69.35%
2010-12-31 $61.59B $42.80B 69.49%
2010-09-30 $62.49B $43.43B 69.49%
2010-06-30 $62.59B $43.69B 69.80%
2010-03-31 $62.50B $43.78B 70.04%
2009-12-31 $61.90B $43.45B 70.20%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $350.533B $85.159B
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $847.248B 122.45
Novo Nordisk (NVO) Denmark $631.845B 48.55
Merck (MRK) United States $324.174B 58.98
AbbVie (ABBV) United States $302.599B 15.64
AstraZeneca (AZN) United Kingdom $243.139B 21.14
Novartis AG (NVS) Switzerland $214.497B 15.21
Pfizer (PFE) United States $155.321B 19.30
Sanofi (SNY) $119.456B 11.27
Innoviva (INVA) United States $1.013B 7.11